Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

Genprex (GNPX) announced that the first patient has been enrolled and dosed in the Phase 2 expansion portion of the company’s Acclaim-3 ...

WATERTOWN, Mass. - Vigil Neuroscience , Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company, has announced the progression of its Alzheimer’s disease (AD) candidate, VG-3927, into a Phase 2 ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

VALORANT's newest competitive year redefined the game's structure with a shift from Episodes to Seasons and new Initiator ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...

In subjects with baseline and week 96 biopsies, 39% of those treated with a 50mg dosage experienced cirrhosis reversal.

What is the moon phase today? Today, Jan. 28, 2025, the moon is 29 days old, in the New Moon phase of its lunar cycle. It is 0% illuminated. Moon phases reveal the passage of time in the night sky.